TESARO, Inc. IPO Info
Company Name: TESARO, Inc.
Stock Symbol: TSRO
IPO Date: 6/28/2012
IPO Price: 13.50 (24.81%)
UnderwritersCitigroup, Morgan Stanley, Leerink Swann, BMO Capital Markets, Baird
Amount of Offering: 103,500,000
Number of Shares Offered: 6 Mil
Shares Outstanding After Offering: 26.67 Mil
Company DescriptionTESARO is an oncology-focused biopharmaceutical company dedicated to improving the lives of cancer patients. The company has in-licensed and is currently developing two product candidates, rolapitant and TSR-011.
- Rolapitant, a potent and long-acting neurokinin-1, or NK-1, receptor antagonist currently in Phase 3 clinical trials for the prevention of chemotherapy induced nausea and vomiting, or CINV; and
- SR-011, an orally available anaplastic lymphoma kinase, or ALK, inhibitor (targeted anti-cancer agent) currently in preclinical development. We plan to test TSR-011 in clinical trials as a treatment for non-small cell lung cancer, or NSCLC, and potentially other cancer indications.